Free Trial
The Market Does Not Wait. MarketBeat All Access for Just $149
Get the Deal
Claim MarketBeat All Access Sale Promotion

Fusion Antibodies (FAB) Competitors

Fusion Antibodies logo
GBX 12.64 -0.61 (-4.63%)
As of 12:29 PM Eastern
Compare

FAB vs. 4BB, ORPH, REDX, ETX, and HVO

Should you buy Fusion Antibodies stock or one of its competitors? MarketBeat compares Fusion Antibodies with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Fusion Antibodies include 4basebio (4BB), Open Orphan (ORPH), Redx Pharma (REDX), e-therapeutics (ETX), and hVIVO (HVO). These companies are all part of the "biotechnology" industry.

How does Fusion Antibodies compare to 4basebio?

Fusion Antibodies (LON:FAB) and 4basebio (LON:4BB) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their risk, profitability, earnings, analyst recommendations, media sentiment, institutional ownership, dividends and valuation.

4basebio has a consensus price target of GBX 1,600, suggesting a potential upside of 207.69%. Given 4basebio's stronger consensus rating and higher possible upside, analysts clearly believe 4basebio is more favorable than Fusion Antibodies.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Fusion Antibodies
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00
4basebio
0 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
3.00

Fusion Antibodies has a beta of 1.215, meaning that its share price is 22% more volatile than the broader market. Comparatively, 4basebio has a beta of 1.09, meaning that its share price is 9% more volatile than the broader market.

7.6% of Fusion Antibodies shares are owned by institutional investors. Comparatively, 0.9% of 4basebio shares are owned by institutional investors. 5.9% of Fusion Antibodies shares are owned by company insiders. Comparatively, 12.1% of 4basebio shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

In the previous week, 4basebio had 8 more articles in the media than Fusion Antibodies. MarketBeat recorded 8 mentions for 4basebio and 0 mentions for Fusion Antibodies. 4basebio's average media sentiment score of 0.71 beat Fusion Antibodies' score of 0.00 indicating that 4basebio is being referred to more favorably in the news media.

Company Overall Sentiment
Fusion Antibodies Neutral
4basebio Positive

Fusion Antibodies has higher earnings, but lower revenue than 4basebio. Fusion Antibodies is trading at a lower price-to-earnings ratio than 4basebio, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Fusion Antibodies£1.60M9.90-£4.10M-£1.50N/A
4basebio£1.78M45.26-£9.84M-£99.00N/A

4basebio has a net margin of 0.00% compared to Fusion Antibodies' net margin of -91.92%. Fusion Antibodies' return on equity of -210.32% beat 4basebio's return on equity.

Company Net Margins Return on Equity Return on Assets
Fusion Antibodies-91.92% -210.32% -63.78%
4basebio N/A -231.29%-54.30%

Summary

4basebio beats Fusion Antibodies on 11 of the 16 factors compared between the two stocks.

How does Fusion Antibodies compare to Open Orphan?

Fusion Antibodies (LON:FAB) and Open Orphan (LON:ORPH) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, dividends, valuation, risk, analyst recommendations, media sentiment, earnings and profitability.

In the previous week, Fusion Antibodies' average media sentiment score of 0.00 equaled Open Orphan'saverage media sentiment score.

Company Overall Sentiment
Fusion Antibodies Neutral
Open Orphan Neutral

Open Orphan has a net margin of 0.00% compared to Fusion Antibodies' net margin of -91.92%. Open Orphan's return on equity of 0.00% beat Fusion Antibodies' return on equity.

Company Net Margins Return on Equity Return on Assets
Fusion Antibodies-91.92% -210.32% -63.78%
Open Orphan N/A N/A N/A

7.6% of Fusion Antibodies shares are owned by institutional investors. 5.9% of Fusion Antibodies shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Open Orphan has higher revenue and earnings than Fusion Antibodies.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Fusion Antibodies£1.60M9.90-£4.10M-£1.50N/A
Open Orphan£34.71M0.00N/AN/AN/A

Summary

Open Orphan beats Fusion Antibodies on 4 of the 7 factors compared between the two stocks.

How does Fusion Antibodies compare to Redx Pharma?

Redx Pharma (LON:REDX) and Fusion Antibodies (LON:FAB) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their valuation, profitability, dividends, media sentiment, risk, institutional ownership, earnings and analyst recommendations.

Redx Pharma has a beta of -0.53, indicating that its share price is 153% less volatile than the broader market. Comparatively, Fusion Antibodies has a beta of 1.215, indicating that its share price is 22% more volatile than the broader market.

In the previous week, Redx Pharma's average media sentiment score of 0.00 equaled Fusion Antibodies'average media sentiment score.

Company Overall Sentiment
Redx Pharma Neutral
Fusion Antibodies Neutral

72.7% of Redx Pharma shares are held by institutional investors. Comparatively, 7.6% of Fusion Antibodies shares are held by institutional investors. 18.4% of Redx Pharma shares are held by insiders. Comparatively, 5.9% of Fusion Antibodies shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Redx Pharma has a net margin of 0.00% compared to Fusion Antibodies' net margin of -91.92%. Redx Pharma's return on equity of -180.80% beat Fusion Antibodies' return on equity.

Company Net Margins Return on Equity Return on Assets
Redx PharmaN/A -180.80% -43.95%
Fusion Antibodies -91.92%-210.32%-63.78%

Fusion Antibodies has lower revenue, but higher earnings than Redx Pharma. Fusion Antibodies is trading at a lower price-to-earnings ratio than Redx Pharma, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Redx Pharma£4.20M0.00-£33.16M-£0.10N/A
Fusion Antibodies£1.60M9.90-£4.10M-£1.50N/A

Summary

Redx Pharma beats Fusion Antibodies on 7 of the 10 factors compared between the two stocks.

How does Fusion Antibodies compare to e-therapeutics?

e-therapeutics (LON:ETX) and Fusion Antibodies (LON:FAB) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their dividends, valuation, analyst recommendations, risk, media sentiment, institutional ownership, earnings and profitability.

e-therapeutics has a beta of 0.46, suggesting that its stock price is 54% less volatile than the broader market. Comparatively, Fusion Antibodies has a beta of 1.215, suggesting that its stock price is 22% more volatile than the broader market.

In the previous week, e-therapeutics' average media sentiment score of 0.00 equaled Fusion Antibodies'average media sentiment score.

Company Overall Sentiment
e-therapeutics Neutral
Fusion Antibodies Neutral

Fusion Antibodies has higher revenue and earnings than e-therapeutics. Fusion Antibodies is trading at a lower price-to-earnings ratio than e-therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
e-therapeutics£295K0.00-£10.06M-£0.02N/A
Fusion Antibodies£1.60M9.90-£4.10M-£1.50N/A

e-therapeutics has a net margin of 0.00% compared to Fusion Antibodies' net margin of -91.92%. e-therapeutics' return on equity of -38.75% beat Fusion Antibodies' return on equity.

Company Net Margins Return on Equity Return on Assets
e-therapeuticsN/A -38.75% -29.10%
Fusion Antibodies -91.92%-210.32%-63.78%

26.5% of e-therapeutics shares are held by institutional investors. Comparatively, 7.6% of Fusion Antibodies shares are held by institutional investors. 59.4% of e-therapeutics shares are held by insiders. Comparatively, 5.9% of Fusion Antibodies shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Summary

e-therapeutics beats Fusion Antibodies on 6 of the 10 factors compared between the two stocks.

How does Fusion Antibodies compare to hVIVO?

Fusion Antibodies (LON:FAB) and hVIVO (LON:HVO) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their risk, analyst recommendations, profitability, dividends, valuation, institutional ownership, media sentiment and earnings.

Fusion Antibodies has a beta of 1.215, suggesting that its share price is 22% more volatile than the broader market. Comparatively, hVIVO has a beta of 1.685, suggesting that its share price is 69% more volatile than the broader market.

In the previous week, hVIVO had 1 more articles in the media than Fusion Antibodies. MarketBeat recorded 1 mentions for hVIVO and 0 mentions for Fusion Antibodies. Fusion Antibodies' average media sentiment score of 0.00 equaled hVIVO'saverage media sentiment score.

Company Overall Sentiment
Fusion Antibodies Neutral
hVIVO Neutral

hVIVO has higher revenue and earnings than Fusion Antibodies. hVIVO is trading at a lower price-to-earnings ratio than Fusion Antibodies, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Fusion Antibodies£1.60M9.90-£4.10M-£1.50N/A
hVIVO£46.77M1.16£17.84M-£0.87N/A

hVIVO has a net margin of -12.48% compared to Fusion Antibodies' net margin of -91.92%. hVIVO's return on equity of -14.65% beat Fusion Antibodies' return on equity.

Company Net Margins Return on Equity Return on Assets
Fusion Antibodies-91.92% -210.32% -63.78%
hVIVO -12.48%-14.65%11.97%

7.6% of Fusion Antibodies shares are owned by institutional investors. Comparatively, 10.2% of hVIVO shares are owned by institutional investors. 5.9% of Fusion Antibodies shares are owned by company insiders. Comparatively, 5.2% of hVIVO shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

hVIVO has a consensus price target of GBX 15, suggesting a potential upside of 90.48%. Given hVIVO's stronger consensus rating and higher possible upside, analysts plainly believe hVIVO is more favorable than Fusion Antibodies.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Fusion Antibodies
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00
hVIVO
0 Sell rating(s)
1 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
2.67

Summary

hVIVO beats Fusion Antibodies on 12 of the 15 factors compared between the two stocks.

Get Fusion Antibodies News Delivered to You Automatically

Sign up to receive the latest news and ratings for FAB and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding FAB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

FAB vs. The Competition

Export
MetricFusion AntibodiesBiotechnology IndustryMedical SectorLON Exchange
Market Cap£15.80M£464.63M£6.38B£2.79B
Dividend YieldN/A3.87%2.79%6.16%
P/E Ratio-8.423.8620.90365.87
Price / Sales9.907,244.58547.4287,741.87
Price / Cash9.0213.1344.1327.89
Price / Book3.6084.7910.097.68
Net Income-£4.10M-£96.07M£3.55B£5.89B
7 Day Performance-18.47%0.79%4.61%1.48%
1 Month Performance-11.00%0.53%1.36%2.30%
1 Year Performance79.32%93.40%36.73%83.78%

Fusion Antibodies Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
FAB
Fusion Antibodies
N/AGBX 12.64
-4.6%		N/A+98.9%£15.80M£1.60MN/A48
4BB
4basebio
2.8165 of 5 stars		GBX 450
+3.4%		GBX 1,600
+255.6%		-55.2%£69.68M£1.78MN/A101
ORPH
Open Orphan
N/AN/AN/AN/A£67.09M£34.71MN/A179
REDX
Redx Pharma
N/AN/AN/AN/A£58.35M£4.20MN/A101
ETX
e-therapeutics
N/AN/AN/AN/A£52.59M£295KN/A35

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (LON:FAB) was last updated on 5/22/2026 by MarketBeat.com Staff.
From Our Partners
How to Profit from Elon’s AI lab before it goes public
Elon Musk's AI lab has partnered with the Department of Defense, Oracle, and Palantir - and he just filed conf...
InvestorPlace | Sponsoredtc pixel
Maybe the Greatest Strategy of the Decade
Nate Bear, Lead Technical Tactician at Monument Traders Alliance, is going public with his highest-conviction ...
Monument Traders Alliance | Sponsoredtc pixel
A letter from Shannon Stansberry
Porter Stansberry nearly canceled the entire project. When he first saw the claimed returns - only one down ye...
Porter & Company | Sponsoredtc pixel
The SpaceX supplier that shipped 5 billion chips to Starlink
When Nvidia surged 770%, its data center cooling supplier Vertiv climbed 1,700%. When Apple ran 2,000%, suppli...
Weiss Ratings | Sponsoredtc pixel
Your $29.97 book is free today
Why Some Traders Skip Stocks Entirely You don't need a big account to trade options. In fact, options ca...
Profits Run | Sponsoredtc pixel
One filing just changed the SpaceX IPO forever
SpaceX just filed its S-1. The IPO is confirmed for June 12 - $75 billion, ticker SPCX, potentially the larges...
Behind the Markets | Sponsoredtc pixel
SpaceX controls two-thirds of all satellites - and it is about to go public
SpaceX is targeting an IPO on June 11th, with trading set to begin June 12th and the roadshow kicking off June...
NXT Wave Research | Sponsoredtc pixel
To Avoid 67 Million Blackouts, Trump Signs Emergency Backing of New Energy Tech
President Trump has used emergency executive powers to back a new energy technology described as 326 times mor...
Altimetry | Sponsoredtc pixel